EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieOpen Access · CC BY-NC 4.0

A Randomized Controlled Phase 3 Trial of Oral Prednisolone Administration Versus Local Triamcinolone Injection Therapy for Esophageal Stricture Prevention After Extensive Endoscopic Submucosal Dissection ( JCOG1217 )

Masaki Tanaka, Hiroyuki Ono, Kohei Takizawa, Shintaro Iwamoto, Yusuke Sano, Seiichiro Abe iD, Tomohiro Kadota iD, Takuya Wada, Akiyoshi Ishiyama, Hiroyoshi Nakanishi, Shinji Nagata, Haruhiko Fukuda und 3 weitere

Digestive Endoscopy · 2026

DOI: 10.1111/den.70195 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive Endoscopy, 2026. Verfasst von Masaki Tanaka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endoscopy, Shimane Prefectural Central Hospital, Izumo, Shimane, Japan. Hauptthemen laut MEDLINE: Prednisolone, Esophageal Stenosis, Triamcinolone, Endoscopic Mucosal Resection. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Center Research and Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Endoscopic local triamcinolone injection is a standard therapy for esophageal stricture (ES) prevention after extensive endoscopic submucosal dissection (ESD); however, oral prednisolone administration is a promising alternative. This trial aimed to investigate the superiority of oral prednisolone administration to local triamcinolone injection for ES prevention after extensive ESD.

Methods

This phase 3, open‐label, multicenter, randomized controlled trial enrolled patients with extensive superficial esophageal squamous cell carcinoma. The primary endpoint was stricture‐free survival (SFS). Secondary endpoints were the number of endoscopic balloon dilations (EBDs) for 12 weeks after ESD, dysphagia score ≤ 1 at 12 weeks after ESD, and adverse events (AEs).

Results

A total of 281 patients from 45 institutions were enrolled. The 12‐week SFS rates were 88.5% (95% confidence interval [CI]: 81.6–92.9) and 94.8% (95% CI: 89.4–97.5) in the triamcinolone and prednisolone arms, respectively (hazard ratio 0.672, 90% CI [0.361–1.250], p = 0.14). Thirty‐eight and 26 EBDs were performed for 14 and 10 patients, respectively, in the triamcinolone and prednisolone arms within 12 weeks after ESD. In the triamcinolone and prednisolone arms, 73.8% (95% CI: 65.7–80.8) and 80.7% (95% CI: 73.2–86.9) of patients, respectively, had dysphagia scores ≤ 1 at 12 weeks after ESD ( p = 0.20). Grade 3/4 AEs occurred in 12 (8.7%) and 9 patients (6.7%) in the triamcinolone and prednisolone arms, respectively.

Conclusions

While oral prednisolone administration and local triamcinolone injection demonstrated comparable outcomes, oral prednisolone did not demonstrate superiority for ES prevention after extensive esophageal ESD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrednisoloneEsophageal StenosisTriamcinoloneEndoscopic Mucosal ResectionEsophageal NeoplasmsPostoperative ComplicationsEsophageal Squamous Cell CarcinomaHumansFemaleMaleAdministration, OralAgedMiddle AgedGlucocorticoidsTreatment OutcomeInjectionsInjections, IntralesionalAnti-Inflammatory Agents

Stichwörter der Autor:innen

endoscopic submucosal dissectionesophageal stricturepreventionrandomized controlled trial

Substanzen

PrednisoloneTriamcinoloneGlucocorticoidsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Division of Endoscopy, Shimane Prefectural Central Hospital, Izumo, Shimane, Japan.
  • Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
  • Division of Gastroenterology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
  • JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
  • Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan.

ORCID-Profile: Seiichiro Abe, Tomohiro Kadota

Förderung

  • National Cancer Center Research and Development Fund

Zitieren

APA

Tanaka, M., Ono, H., Takizawa, K., Iwamoto, S., Sano, Y., Abe, S., Kadota, T., Wada, T., Ishiyama, A., Nakanishi, H., Nagata, S., Fukuda, H., Muto, M., Yano, T., & Gastrointestinal Endoscopy Study Group of the Japan Clinical Oncology Group (2026). A Randomized Controlled Phase 3 Trial of Oral Prednisolone Administration Versus Local Triamcinolone Injection Therapy for Esophageal Stricture Prevention After Extensive Endoscopic Submucosal Dissection ( JCOG1217 ). Digestive Endoscopy. https://doi.org/10.1111/den.70195

Vancouver

Tanaka M, Ono H, Takizawa K, Iwamoto S, Sano Y, Abe S, et al. A Randomized Controlled Phase 3 Trial of Oral Prednisolone Administration Versus Local Triamcinolone Injection Therapy for Esophageal Stricture Prevention After Extensive Endoscopic Submucosal Dissection ( JCOG1217 ). Digestive Endoscopy. 2026. doi:10.1111/den.70195

BibTeX
@article{Tanaka2026,
  author = {Tanaka, Masaki and Ono, Hiroyuki and Takizawa, Kohei and Iwamoto, Shintaro and Sano, Yusuke and Abe, Seiichiro and Kadota, Tomohiro and Wada, Takuya and Ishiyama, Akiyoshi and Nakanishi, Hiroyoshi and Nagata, Shinji and Fukuda, Haruhiko and Muto, Manabu and Yano, Tomonori and Gastrointestinal Endoscopy Study Group of the Japan Clinical Oncology Group, Gastrointestinal Endoscopy Study Group of the Japan Clinical Oncology Group},
  title = {A Randomized Controlled Phase 3 Trial of Oral Prednisolone Administration Versus Local Triamcinolone Injection Therapy for Esophageal Stricture Prevention After Extensive Endoscopic Submucosal Dissection ( JCOG1217 )},
  journal = {Digestive Endoscopy},
  year = {2026},
  doi = {10.1111/den.70195}
}
Kostenlos starten →